Boston Scientific (BSX) Tops Q4 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
Tweet
Share
E-mail
Get Alerts BSX Hot Sheet
Price: $43.72 +0.88%
EPS Growth %: +5.3%
Financial Fact:
Interest expense: -58M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: +5.3%
Financial Fact:
Interest expense: -58M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.80, $0.02 better than the analyst estimate of $0.78. Revenue for the quarter came in at $5.29 billion versus the consensus estimate of $5.28 billion.
GUIDANCE:
Boston Scientific sees FY2026 EPS of $3.43-$3.49, versus the consensus of $3.47.
For earnings history and earnings-related data on Boston Scientific (BSX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GameStop CEO Cohen buys 1.15M shares
- Cematrix wins $8.8M in new contracts, bringing YTD total to $43.2M
- CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
